Company Overview and News
Peninsula Energy Ltd (ASX:PEN) will be keeping a close eye on a nine-month investigation by the US Department of Commerce (DOC) into domestic uranium supply.
Peninsula Energy Ltd (ASX:PEN) has exceeded quarterly uranium production expectations despite suspending the majority of alkaline-based production within the first mining unit (MU1) at the Lance Projects in Wyoming, USA.
The operators in the Athabasca Basin, Canada, enjoy the highest-grade uranium deposits and have a geological edge over other uranium districts.
PALAY PEN RIO LAM BLT AZZ TOEYF SYH PDN UEXCF PALAF NXE UEC EFR BMN UUUU.WS LMRXF FSY DNN PWURF CVV RIO BBL GVXXF BHPLF FCU SYHBF DYLLF RIO NXGEF BKY ISENF CVVUF WSTRF RTPPF FOSYF TOE RTNTF CCJ UUUU DYL PENMF UWEFF KVLQF TGRUF MGAFF PDN BHPBF FCUUF EU URG DML BKY MGA PUMGF BHP BNNLF 9888 BHP LAM
Peninsula Energy Ltd's (ASX:PEN) recent selling pressure has now stopped following Global X Uranium Exchange Traded Fund reducing its holding to less than 5%.
Peninsula Energy Ltd (ASX:PEN) managing director and CEO Wayne Heili speaks to Proactive Investors about the transformational work the uranium mining company has been undertaking at its flagship Lance Project in Wyoming in the US; known as the 'low pH transformation initiative.'
Peninsula Energy Ltd (ASX:PEN) has completed a block trade of the majority of shares held by Global X Uranium ETF in Peninsula to clients of Patersons Securities.
Peninsula Energy Ltd (ASX:PEN) is in the process of transitioning from alkaline-based production to low pH operations at its Lance Project in US state of Wyoming.
Peninsula Energy Ltd (ASX:PEN) is hitting its straps with the uranium producer exceeding the top end of production guidance of 40,000 pounds at its Lance project in the March quarter.
Peninsula Energy Ltd (ASX:PEN) has entered into binding offer letters with major shareholders Resource Capital Fund VI L.P. (RCF VI) and Pala Investments Ltd.
Peninsula Energy Ltd (ASX:PEN) has submitted a request to the Wyoming Department of Environmental Quality (WDEQ) to allow the use of a low-pH recovery solution in the Ross Permit Area of its Lance Projects in Wyoming, US.
8h - Asif
Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
Silicon Investor Message Boards
This table lists all message boards related to ASX:PEN / PENINSULA ENERGY LIMITED on message board site Silicon Investor.